Cargando…

Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study

BACKGROUND: Heart failure (HF) is a global leading cause of mortality despite implementation of guideline directed therapy which warrants a need for novel treatment strategies. Proof-of-concept clinical trials of anakinra, a recombinant human Interleukin-1 (IL-1) receptor antagonist, have shown prom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Tassell, Benjamin, Mihalick, Virginia, Thomas, Georgia, Marawan, Amr, Talasaz, Azita H., Lu, Juan, Kang, Le, Ladd, Amy, Damonte, Juan Ignacio, Dixon, Dave L., Markley, Roshanak, Turlington, Jeremy, Federmann, Emily, Del Buono, Marco Giuseppe, Biondi-Zoccai, Giuseppe, Canada, Justin M., Arena, Ross, Abbate, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198622/ https://www.ncbi.nlm.nih.gov/pubmed/35706006 http://dx.doi.org/10.1186/s12967-022-03466-9

Ejemplares similares

Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction
por: Del Buono, Marco Giuseppe, et al.
Publicado: (2022)

277 Heart Failure Clinical Trial Enrollment at a Rural Satellite Hospital
por: Abbate, Antonio, et al.
Publicado: (2022)

Interleukin‐1 blockade in heart failure: an on‐treatment and off‐treatment cardiorespiratory fitness analysis
por: Moroni, Francesco, et al.
Publicado: (2023)

Differential Response to Interleukin‐1 Blockade With Anakinra on Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction Stratified According to Left Ventricular Ejection Fraction
por: Golino, Michele, et al.
Publicado: (2023)

Change in Eosinophil Count in Patients with Heart Failure Treated with Anakinra
por: Golino, Michele, et al.
Publicado: (2023)

Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure
por: Wohlford, George F., et al.
Publicado: (2021)

Cardiopulmonary exercise testing during the COVID-19 pandemic
por: Mihalick, Virginia L., et al.
Publicado: (2021)

Abnormal left ventricular subendocardial perfusion and diastolic function in women with obesity and heart failure and preserved ejection fraction
por: Markley, Roshanak, et al.
Publicado: (2023)

Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction
por: Abbate, Antonio, et al.
Publicado: (2020)

Edema Index Predicts Cardiorespiratory Fitness in Patients With Heart Failure With Reduced Ejection Fraction and Type 2 Diabetes Mellitus
por: Marawan, Amr, et al.
Publicado: (2021)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
por: Chatterjee, Saurav, et al.
Publicado: (2013)

The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA‐HF study
por: Carbone, Salvatore, et al.
Publicado: (2020)

3426 Increased Monounsaturated Fat Consumption is Associated with Improved Body Composition in Subjects with Obesity and Heart Failure with Preserved Ejection Fraction
por: Billingsley, Hayley, et al.
Publicado: (2019)

Portal Vein Thrombosis in Decompensated Cirrhosis: Rationale for Treatment
por: Senzolo, Marco, et al.
Publicado: (2019)

Impaired myocardial relaxation with exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction
por: Trankle, Cory, et al.
Publicado: (2017)

Low NT‐proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction
por: Buckley, Leo F., et al.
Publicado: (2018)

Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale
por: Samsonov, M., et al.
Publicado: (2021)

Cardiologic side effects of psychotropic drugs
por: Marano, Giuseppe, et al.
Publicado: (2011)

Postinfarction Ventricular Septal Rupture: Identification of the Failure Mechanism of a Percutaneous Closure Procedure
por: Bachini, Juan P., et al.
Publicado: (2022)

Network Meta-analysis to Synthesize Evidence for Decision Making in Cardiovascular Research
por: Roever, Leonardo, et al.
Publicado: (2016)

Late Pseudoaneurysm after Manta Use for Transfemoral Aortic Valve Implantation: A Call for Caution?
por: Roever, Leonardo, et al.
Publicado: (2018)

Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective
por: Talasaz, Azita Hajhossein, et al.
Publicado: (2020)

Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART)
por: Kron, Jordana, et al.
Publicado: (2021)

The Potential Role of Clinical Pharmacy Services in Patients with Cardiovascular Diseases
por: Talasaz, Azita Hajhossein
Publicado: (2012)

Heart, Lung and Vessels... but brain and hands too! The case for a novel journal in the cardiovascular scholarly arena
por: Peruzzi, Mariangela, et al.
Publicado: (2015)

Individualised prognosis in out-of-hospital cardiac arrest: The case for P-ROSC in Asian people
por: Testa, Alberto, et al.
Publicado: (2022)

Air pollution and cardiovascular risk: is it time to change guidelines?
por: Bernardi, Marco, et al.
Publicado: (2022)

When early discharge after percutaneous coronary intervention is much too early
por: Siudak, Zbigniew, et al.
Publicado: (2022)

Out-of-hospital cardiac arrest: predict and then protect!
por: Spadafora, Luigi, et al.
Publicado: (2023)

Orthostatic intolerance syndromes after hematopoietic cell transplantation: clinical characteristics and therapeutic interventions in a single-center experience
por: Vecchié, Alessandra, et al.
Publicado: (2021)

A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers
por: Wohlford, George F., et al.
Publicado: (2021)

C-Reactive Protein and N-Terminal Pro-brain Natriuretic Peptide Levels Correlate With Impaired Cardiorespiratory Fitness in Patients With Heart Failure Across a Wide Range of Ejection Fraction
por: van Wezenbeek, Jessie, et al.
Publicado: (2018)

Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
por: Bonaventura, Aldo, et al.
Publicado: (2020)

Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the Mouse
por: Toldo, Stefano, et al.
Publicado: (2013)

Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic
por: Sedhai, Yub Raj, et al.
Publicado: (2021)

Bridging the Gap between Translational and Outcome Research in Cardiovascular Disease
por: Frati, Giacomo, et al.
Publicado: (2015)

Hemostasis After Brachial Artery Access With the MynxGrip Device: A Case Report
por: Giordano, Arturo, et al.
Publicado: (2018)

Cardiotoxicity due to chemotherapy for breast cancer: The dark side of the moon
por: Peruzzi, Mariangela, et al.
Publicado: (2015)

Veneto's Successful Lesson for a World Shocked by COVID-19: Think Globally and Act Locally
por: Cavarretta, Elena, et al.
Publicado: (2020)

Electronic cigarette
por: Biondi Zoccai, Giuseppe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s3bcapgssr59m4nebqaq57jeth